The acquisition of ZIP Solutions strengthens the presence of Bionaturis Group in BIOSPAIN 2016, the biggest country-based event in Europe. The main goal of the biotechnological group in this international forum is increasing the number of national and international customers. In order to achieve this goal, Bionaturis Group will showcase the competitive advantages of our premium services of development of biotechnological active principles for human and animal health and preclinical research by using Zebrafish as animal model.

The capacity of Bionaturis Group has grown up recently after acquisition ZIP, including its two proprietary technologies – Zera® and Splittera. Both technologies are key for improving the design of biological active principles. Zera® leads to increasing production yields in any type of biofactory.  Additionally, it improves the antigenic properties of vaccines. Splittera -worldwide out-licensed to a leading multination company- is a revolutionary technology making protein purification by affinity more simple and universal. It also provides new methods for making antibody-drug conjugates and improvement reagents in diagnostics. After joining ZIP’s assets to those of Bionaturis and Biobide –a company specialized in development of toxicity and efficacy preclinical assays in Zebrafish -, “our total offer brings together into the same biotechnological group innovative and highly specialized solutions that have already built loyalty among customers from different sectors: companies making active principles for agriculture, livestock, petrochemical, cosmetics; pharmaceutical companies developing new candidates for cancer and minority diseases; or industrial groups leaders in offering technologies for production in biotechnology. In BIOSPAIN we are going to show why our services have given competitive advantages to these companies”, the Chief Scientific Officer, Juan Jose Infante, has stated.

The event, organized by the Spanish Association for Biotech Companies (ASEBIO, in Spanish), and SPRI (the Basque Agency for Business Development) will be held since 28 to 30th September, 2016, at the Bilbao Exhibition Centre (BEC) in Barakaldo (Bilbao). Bionaturis Group is very attractive to this year’s BIOSPAIN not only because of the location of the event -only a few kilometers from Biobide’s headquarters- but also because of the participation of USA in the event as guest country. USA’s market is one of the strategic expansion markets for Bionaturis Group, especially for Biobide, which signed a contract with the National Institute of Environmental Health Sciences (NIEHS) and has a subsidiary in the state of Maryland.

“In Biospain 2016 we will show how to design and produce improved vaccines and treatments for key sectors in animal health or how to access to services for testing toxicity and efficacy of new leads under the quality standards required for regulatory approval and registration. During our lecture in the Services Pavilion on the 29th at 10.30 am we will talk about the experiences that built loyalty among our customers and partners. We look for new experiences by increasing our portfolio and therefore make progress in our mission of improving the global access to health. This year at BioSpain 2016 we will present the best offer up to date and we play at home, thus our expectations are very high”, the manager has explained.

Bionaturis Group’s delegates in BioSpain 2016 will be Bionaturis’ Chief Scientific Officer Dr. Juan J. Infante,  Biobide’s R&D Management Director Dr. Arantza Muriana; Biobide’s General Manager Mr. Andoni Cruz; and ZIP Solutions’ General Manager Dr. Miriam Bastida. The companies within Bionaturis Group will be present at the Biobasque Pavilion (Pavilion 1, booth 15), the Services Pavilion, and the Partnering Zone.

To arrange a meeting with Bionaturis Group companies at BioSpain, please, send an email to

The relevance of BIOSPAIN 2016

In addition to the presence of USA as guest country, another of the main novelties in BIOSPAIN 2016 is the expansion of the commercial area up to 40% relative to previous editions. The relevance of this forum is getting bigger, as indicated by recent statistics showing visitors from 37 different nationalities, 50 investment funds –80% international funds- and celebration of more than 3,300 business meetings.

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT). In addition to this new acquisition, Bionaturis Group has other two locations in Spain (Bionaturis and Biobide) and two subsidiaries in the USA and China.